• Users Online: 398
  • Print this page
  • Email this page
STATE-OF-THE-ART REVIEW
Year : 2013  |  Volume : 6  |  Issue : 2  |  Page : 121-128

Biomarkers for screening and early detection of prostate cancer


1 Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, USA; Department of Urology, University Hospital Basel, Switzerland
2 Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, USA; Department of Urology, Medical University of Vienna, Vienna, Austria

Correspondence Address:
Shahrokh F Shariat
Department of Urology, Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7707/hmj.v6i2.277

Rights and Permissions

Prostate cancer (PCa) represents a significant health burden and the high prevalence and natural course of the untreated disease make PCa ideal for screening and early detection. The aim of this review is to give an overview of the recent evidence on biomarkers for screening and early detection of PCa. A review of the current literature on prostate-specific antigen (PSA) and novel biomarkers in PCa diagnosis and screening was conducted using MEDLINE/PubMed to identify relevant publications. PSA is currently the main biomarker for PCa screening and diagnosis, and two out of three recent randomized controlled trials on PSA screening for PCa showed a 20–40% risk reduction of PCa-specific mortality in the screened group. In contrast, one study did not show any beneficial effect of PSA screening. Although each study had flaws, the study that reported no benefit from PSA screening had a high contamination rate in the control group and non-compliance in the screening group. However, PCa screening was associated with overdiagnosis, which led to overtreatment. Therefore, there is a need for novel biomarkers that are more specifically associated with PCa and its biological and clinical behaviour. Several such biomarkers are currently being investigated as an adjunct to PSA; however, none can currently replace PSA. Among novel biomarkers, PCa antigen 3 (PCA3) and TMPRSS2–ERG gene fusions appear to be most promising and, currently, PCA3 is reported as the more efficient diagnostic test in patients who have had a previous negative biopsy.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed184    
    Printed7    
    Emailed0    
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal